期刊
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
卷 13, 期 1, 页码 150-156出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1055-9965.EPI-082-3
关键词
-
资金
- NCI NIH HHS [5K08CA089029-02, R21CA102220] Funding Source: Medline
- NATIONAL CANCER INSTITUTE [R21CA102220, K08CA089029] Funding Source: NIH RePORTER
The Ataxia-telangiectasia-mutated (ATM) gene product is a well-characterized tumor suppressor that plays a key role in maintenance of genomic stability. We have recently documented that the ATM promoter is a target for epigenetic silencing in cultured tumor cells. Here we show that aberrant methylation of the ATM promoter occurs in a significant percentage (25%) of head and neck squamous cell carcinomas. The presence or methylated ATM promoter shows a statistically significant correlation with an earlier age of initial diagnosis and decreased overall survival, particularly in early-stage tumors. These findings indicate that ATM promoter hypermethylation occurs in head and neck squamous cell carcinoma, and this feature is a potentially useful prognostic marker in this tumor type.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据